AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo

AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo

Abstract Cardiac hypertrophy is one of the most common genetic heart disorders and considered a risk factor for cardiac morbidity and mortality. The mammalian target of rapamycin (mTOR) pathway plays a key regulatory function in cardiovascular physiology and pathology in hypertrophy. AZD2014 is a sm...

Full description

Bibliographic Details
Main Authors: Byung-Hyun Cha, Minjin Jung, Angela S. Kim, Victoria C. Lepak, Brett A. Colson, David A. Bull, Youngwook Won
Format: Article
Language:English
Published: BMC 2021-10-01
Series:Journal of Biological Engineering
Subjects:
AZD2014
Cardiomyocyte
Cardiac hypertrophy
mTOR inhibitor
Online Access:https://doi.org/10.1186/s13036-021-00276-3

Internet

https://doi.org/10.1186/s13036-021-00276-3

Similar Items